___

• 1. Gómez Martinez MV, Gallardo FG, Pirogova T, GarcíaSamaniego J. Bone scintigraphy and secondary osteomalacia due to nephrotoxicity in a chronic hepatitis B patient treated with tenofovir. Rev Esp Med Nucl Imagen Mol 2014; 33: 103- 105.
• 2. Mateo L, Holgado S, Marinoso ML, Andres RP, Bonjoch A, Romeu J, Olive A. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol 2016; 35: 1271-1279
• 3. Buchacz K, Brooks JT, Tong T, Moorman AC, Baker RK, Holmberg SD, Greenberg A, Wood KC, Armon C, Richardson JT et al. Evaluation of hypophosphatemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Medicine 2006; 7: 451-456.
• 4. Wainwright E, Sherrard J, Duncan S, Shine B, Dorrell L. Hypophosphataemia with non-tenofovir-containing antiretroviral therapy. Int J STD AIDS 2013; 24: 579-581.
• 5. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn Pet al. Dig Dis Sci 2015; 60: 1457-1464.
• 6. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014; 146: 980-988.